| |
|
|
| |
EVENT DETAILS |
<P><A HREF="http://www.celdaramedical.com/site-administrator/new-york-city" TARGET="_blank" REL="noopener noreferrer noopener nofollow noopener noreferrer nofollow nofollow noreferrer nofollow">Celdara Medical NYC</A> would like to invite you to attend ourPitch competition and Networking event which will be held on December 14th, 2016 at the New York Blood center.</P>
<P><SPAN>Come listen to Celdara Medical NYC Interns pitch company development strategies for early stage technologies and stay for the post-pitch networking session</SPAN><EM><STRONG>.</STRONG></EM></P>
<P><STRONG>Agenda</STRONG></P>
<P>Pitch Competition:3:30-5:00 pm</P>
<P>Networking Reception:5:00-6:30 pm<EM><STRONG>Sponsored By Genmab</STRONG></EM></P>
<P><BR></P>
<P><STRONG>Judges' Panel<I>:</I></STRONG></P>
<P>Kathleen Denis, Associate VP at Rockefeller University;</P>
<P>Peter Donnelly, Director at OITD Stony Brook University & Manager of Accelerate LI;</P>
<P>Sam Kongsamut, Executive Director at Institute for Life Science Entrepreneurship (ILSE)</P>
<P>Derek Brand, CEO at Quicksilver Genomics</P>
<P>Sam Hall, Principal at Apple Tree Partners</P>
<P>Bruce Conway, Program Director at Rockefeller University</P>
<P>Christopher Halliday, Partner at Morgan Lewis & Bockius</P>
<P><BR></P>
<P><SPAN><STRONG>About Celdara Medical</STRONG></SPAN></P>
<P>Celdara Medical builds lasting partnerships with inventors and their institutions, and provides the developmental, financial, andbusiness acumen to bridge the gap between discovery and clinical impact. Celdara has been in the New York City biotechcommunity since 2014 and specializes in therapeutic development across all disease spaces.<A HREF="http://www.celdaramedical.com/site-administrator/new-york-city" TARGET="_blank" REL="noopener noreferrer noopener nofollow noopener noreferrer nofollow nofollow noreferrer nofollow">http://www.celdaramedical.com</A></P>
<P><STRONG>About Genmab</STRONG></P>
<P>Genmab is a publicly traded, international biotechnology company specializing in the creation and development ofdifferentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies,Arzerra (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX (daratumumab)for the treatment of heavily pretreated or double refractory multiple myeloma. Genmab's technology base consists of validatedand proprietary next generation antibody technologies - the DuoBody platform for generation of bispecific antibodies, and theHexaBody platform which creates effector function enhanced antibodies.</P>
|
|
|
|
|
|
